Cargando…
Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer
BACKGROUND: Both obesity and over-expression of HER II are associated with poor prognosis of breast cancer. In vitro experiments suggest that anti-tumour activity of the anti-obesity drug Orlistat is likely to be due to transcriptional suppression of HER II expression. The overexpression of HER II i...
Autores principales: | Sellahewa, Chaminda, Nightingale, Peter, Carmichael, Amtul R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266765/ https://www.ncbi.nlm.nih.gov/pubmed/18294401 http://dx.doi.org/10.1186/1477-7800-5-2 |
Ejemplares similares
-
Women with large breasts are at an increased risk of advanced breast cancer
por: Sellahewa, Chaminda, et al.
Publicado: (2008) -
Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012) -
Obesity in post menopausal women with a family history of breast cancer: prevalence and risk awareness
por: Begum, Parvin, et al.
Publicado: (2009) -
Overexpression of MTFR2 Predicts Poor Prognosis of Breast Cancer
por: Lu, Wenjie, et al.
Publicado: (2020) -
FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)